Advanced Filters
noise

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

Found 761 clinical trials
C Carisa Cooney, MPH,CCRP

Human Craniomaxillofacial Allotransplantation

Background: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from society. Although current surgical advancements can somewhat restore facial …

18 - 65 years of age All Phase 2
M Meg Thomas

Study of Treatment for HPV16+ ASC-US or LSIL

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

19 years of age Female Phase 1

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a …

18 - 80 years of age All Phase 2
R Rajani Sebastian, PhD

Cerebellar Stimulation for Aphasia Rehabilitation

The optimal site of neuromodulation for post-stroke aphasia has yet to be established. This study will investigate whether multiple sessions of cerebellar transcranial direct current stimulation (tDCS) boosts language therapy in helping people recover from aphasia as well as predict who is likely to respond to cerebellar tDCS.

18 - 99 years of age All Phase N/A
A Ala Elhelali, PhD

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

The aim of this clinical trial is to assess the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will allow for faster and greater recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity …

18 years of age All Phase 2
D David Loeb, MD

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to …

12 - 40 years of age All Phase 1/2
L Lorenzo Leggio, M.D.

Spironolactone in Alcohol Use Disorder (SAUD)

Background Alcohol use disorder (AUD) affects about 29.5 million people in the United States. Only 3 medicines have been approved by Food and Drug Administration to treat AUD. Researchers want to find better treatments for AUD. Animal studies found that a medicine called spironolactone, may decrease the amount of alcohol …

21 - 99 years of age All Phase 1
S Samantha Horn

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

60 - 95 years of age All Phase 2
B Brooke Paskewich, Ph.D.

Coaching Teachers in Bullying Detection and Intervention

The investigators' overall objective is to demonstrate the efficacy of the Bullying Classroom Check-Up (BCCU) on elementary aged students' aggressive and bullying behaviors, teacher practices, and student and teacher relationships. The investigators' principal hypothesis is that the BCCU will improve students' aggression and bullying behaviors and their perceptions of the …

8 - 99 years of age All Phase N/A

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

18 years of age All Phase 1

Simplify language using AI